An interventional study of Vasopressin and Placebo in Healthy, sponsored by University of Electronic Science and Technology of China. Recruiting at 1 site in China. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-11.
Sponsored by University of Electronic Science and Technology of China · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing Arginine Vasopressin in Diabetes Insipidus — 12 open to participants now, 12 under way, 2 of them phase 3. Arginine Vasopressin · Diabetes Insipidus.
Among the 43 studies testing Arginine Vasopressin in Diabetes Insipidus, this one is the 25th largest by planned enrollment, is one of 4 that started in 2024, is one of 17 with no phase, reaches primary completion later than 2 of the 11 other live ones, and was the 38th registered.
191 studies on the registry are indexed under Diabetes Insipidus; 35 are open to participants now.
Browse Diabetes Insipidus studies →12 of the 43 studies testing Arginine Vasopressin in Diabetes Insipidus are open now, in 5 countries. Recruiting first, the newest first:
Tiohundra AB · Sites in Sweden
Ages 18+
University of Electronic Science and Technology of China · Sites in China
Ages 18–30 · Healthy volunteers
The Cleveland Clinic · Sites in United States
Ages 18+
Jason Sperry · Sites in United States
Ages 18–90
University of Electronic Science and Technology of China · Sites in China
Ages 18–40 · Healthy volunteers
By country, each count listing its studies:
Arginine Vasopressin: first FDA approval 2020 (VASOPRESSIN). What it is approved for, and how studies give it, is on its page →
Of the 30 Diabetes Insipidus studies recruiting now, 16 (53%) set no upper age limit and 11 (37%) stop at 75 or younger; 4 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 9 · Phase 4 8
First in 2000; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is close to the median of 77 across 118 interventional studies indexed under Diabetes Insipidus.
Median enrollment 105 across the 43 interventional studies. Of the 25 that completed or were terminated, 7 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 43 have an industry lead sponsor. The 10 most frequent:
University of Electronic Science and Technology of China is the lead sponsor of 112 studies on the registry; 37 are open to participants now.
University of Electronic Science and Technology of China has 7 studies filed under Diabetes Insipidus — fewer than ten, so there is no comparison to draw.
5 of the studies testing Arginine Vasopressin in Diabetes Insipidus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04053478Samuel Lunenfeld Research Institute, Mount Sinai HospitalEffects of Ephedrine, Phenylephrine, Norepinephrine and Vasopressin on Contractility of Human Myometrium and Umbilical Vessels: An In-vitro Study | 2026-12 |
| NCT07838493University of Electronic Science and Technology of ChinaOromucosal Oxytocin and Vasopressin Modulation of Emotional Face Attention | 2026-12-18 |
| NCT03446456University of Maryland, BaltimoreVasopressin and Pain Perception in the Brain | 2026-12-31 |
| NCT05958342Jason SperryCAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial | 2027-03 |
| NCT06709573The Cleveland ClinicEarly Versus Late Adjunctive Vasopressin in Septic Shock | 2027-05-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 43 studies testing Arginine Vasopressin in Diabetes Insipidus, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on the perception of time-to-collision of threatening and non-threatening stimuli by combining a validated looming fear eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.
Animal models and initial findings in humans suggest a role of the AVP signaling system in socio-emotional processes. At the same time, the visual system's remarkable ability to perceive and interpret impending threats, notably through the "looming" phenomenon- a distinct pattern of optical expansion on the retina as objects approach, theoretically allows for precise estimation of the time-to-collision (TTC). It was recently demonstrated that the affective content of looming stimuli influences perceived TTC, with threatening objects judged as approaching sooner than non-threatening objects, hinting at a nuanced interaction between emotional valence and temporal perception. Within this context the present study aims to validate the effects of orally administered on the perception of time-to-collision of threatening and non-threatening stimuli. To this end, healthy individuals will undergo a double-blind, between-subjects, placebo-controlled pharmaco-eye-tracking experiment and receive a single oral dose of vasopressin (20 IU) or placebo before performing a looming visual stimuli task 45 minutes after administration. The task paradigm will encompass threatening (butterfly, rabbit) and non-threatening (spider, snake) stimuli
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Vasopressin (20IU)
Drug: Vasopressin
Drug: Placebo
Drug: Placebo
Administration of vasopressin (20 IU) (oral spray)
Also known as: Antidiuretic Hormone
Administration of placebo (oral spray)
Also known as: Placebo treatment
Ratio of judged-time-to-collision to actual-time-to-collision for threatening versus non-threatening stimuli after oral vasopressin administration
Comparison of the ratio between the judged time to collision and the actual time to collision between the treatment groups for threatening (spider, snake) and non-threatening (rabbit, butterfly) stimuli.
Time frame: 75 minutes - 105 minutes after treatment
First saccade latency(ms) for threatening versus non-threatening stimuli after oral vasopressin administration
Comparison of first saccade latencies between treatment groups for threatening (spider, snake) and non-threatening (rabbit, butterfly) stimuli.
Time frame: 75 minutes - 105 minutes after treatment
Fixation duration(ms) for threatening versus non-threatening stimuli after oral vasopressin administration
Comparison of mean fixation durations between treatment groups for threatening (spider, snake) and non-threatening (rabbit, butterfly) stimuli.
Time frame: 75 minutes - 105 minutes after treatment
Started Mar 2024 (actual). Primary completion is estimated for Jun 2025, 14 months after the start.
Of 37 non-industry interventional studies with no phase under Diabetes Insipidus, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 44. This study's planned 14 months is below that.
Counting every sponsor, half of 37 studies reached it within 20 months; a quarter within 8 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arginine Vasopressin
University of Electronic Science and Technology of China →